WO2024134859A1 - 製造中間体 - Google Patents
製造中間体 Download PDFInfo
- Publication number
- WO2024134859A1 WO2024134859A1 PCT/JP2022/047526 JP2022047526W WO2024134859A1 WO 2024134859 A1 WO2024134859 A1 WO 2024134859A1 JP 2022047526 W JP2022047526 W JP 2022047526W WO 2024134859 A1 WO2024134859 A1 WO 2024134859A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- added
- water
- production
- producing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Definitions
- the present invention relates to a novel intermediate in the production of an oxoisoquinoline derivative having BTK inhibitory activity and a method for producing the intermediate.
- BTK Bruton's tyrosine kinase
- Patent Document 1 discloses 2-(3- ⁇ 2-amino-6-[1-(oxetan-3-yl)-1,2,3,6-tetrahydropyridin-4-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl ⁇ -2-(hydroxymethyl)phenyl)-6-cyclopropyl-8-fluoroisoquinolin-1(2H)-one (hereinafter, compound (A)): is exemplified.
- compound (A)) is extremely difficult to carry out on a semi-industrial or industrial scale. It was necessary to find a production method suitable for practical production by further improving the operability, purification efficiency, yield, etc. of the production.
- the present invention provides a novel intermediate and a process for producing oxoisoquinoline derivatives more economically and in higher yields using the intermediate. Furthermore, the process described herein allows for economical cost reduction of intermediates and results in higher yields overall, compared to currently known processes (such as those described in Patent Document 1).
- the method for producing the compound (A) provided by the present invention is as follows. (1) A production method in which compound (Ia) is oxetanylated to produce compound (Ib), which is then reacted with known compound (B) to obtain the target compound (A).
- a method for producing compound (A) in the above-mentioned production method (1) which comprises using compound (Ia) obtained by chlorinating compound (III) and then deprotecting the trifluoroacetyl group.
- a method for producing compound (A), comprising reacting compound (VII) with a brominating agent, and then reacting the resulting compound with compound (VI) in the above-mentioned production method (4), to produce compound (V).
- the present invention also provides compound (Ia), which is an intermediate for producing compound (A), and a method for producing the same, as described below.
- a method for producing compound (Ia) comprising reacting compound (VII) with a brominating agent, and then reacting the resulting compound with compound (VI) in the above-mentioned production method (9), to produce compound (V).
- the manufacturing method of the present invention using the novel manufacturing intermediates allows the target compound (A) to be manufactured more economically and in higher yields. Furthermore, the method described in this specification allows for a process that can reduce the cost of manufacturing intermediates economically compared to currently known manufacturing methods (such as those described in Patent Document 1), resulting in a higher overall yield.
- Compound (II) can also be concentrated without isolating it, and treated with aqueous ammonia to prepare compound (Ia).
- (2-2) Production of Compound (A) The target compound (A) is produced from the compound (Ia) obtained above through the aforementioned step (1).
- step (3) treating compound (IV) with trifluoroacetic anhydride to produce compound (III);
- the target compound (A) is produced through the above-mentioned step (2).
- (3-1) Preparation of Compound (III) In acetonitrile or 1,2-dichloroethane, preferably acetonitrile, compound (IV) is reacted with trifluoroacetic anhydride in the presence of an amine compound.
- the amine compound is selected from triethylamine, pyridine, and 2,6-lutidine, with 2,6-lutidine being preferred.
- the product, compound (IV) can be isolated as either the free base or the hydrochloride salt, preferably as the hydrochloride salt.
- (4-2) Production of Compound (A) The target compound (A) is produced from the compound (IV) obtained above through the aforementioned step (3).
- the reaction of the bromo compound (X) with the diaminopyrimidine (VI) is carried out in acetic acid or a mixture of acetic acid and water. When a mixture of acetic acid and water is used, the ratio of water is preferably 1% to 90%.
- the reaction temperature is 50°C to 90°C, preferably 70°C to 85°C.
- the compound (VII) used as the raw material for the above (5-1) can be produced from anise alcohol (IX), for example, as shown in the following scheme.
- anise alcohol (IX) is reacted with hydrogen bromide to form 4-methoxybenzyl bromide, which is then reacted with compound (VIII).
- the reaction of anisalcohol (IX) with hydrogen bromide is carried out in a solvent selected from toluene, dichloromethane and chloroform, with hydrogen bromide being added as an aqueous solution.
- the reaction temperature is 0°C to 50°C, more preferably 15°C to 30°C.
- the product 4-methoxybenzyl bromide may be isolated once and then used in the next reaction, or may be used in the form of a solution dissolved in a reaction solvent.
- the subsequent reaction with compound (VIII) is carried out in a solvent selected from toluene, dichloromethane and chloroform, at a reaction temperature of 0°C to 50°C, preferably 15°C to 30°C.
- the product compound (VII) can be easily isolated as a solid, and is preferably used in the next step after isolation.
- the following formula (Ia): or a salt thereof is a production intermediate for producing compound (A) and is included in the present invention.
- the following is an embodiment of the invention for producing this production intermediate.
- step (6) preparing compound (III) by treating compound (IV) with trifluoroacetic anhydride;
- step (6) is carried out to produce the production intermediate (Ia).
- the production of compound (III) is as described in the above step (3-1).
- step (7) preparing compound (IV) by treating compound (V) with sodium borohydride;
- step (7) is carried out to produce the production intermediate (Ia).
- the production of compound (IV) is as described in the above step (4-1).
- step (9) reacting compound (VII) with a brominating agent, and then reacting it with diaminopyrimidine (VI) to produce compound (V);
- step (8) is carried out to produce the production intermediate (Ia).
- the compound (V) can be produced as described in the above step (5-1).
- Step 2 4-(2-amino-4-hydroxy-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-1-(4-methoxybenzyl)pyridin-1-ium bromide (V)
- 4-acetyl-1-(4-methoxybenzyl)pyridin-1-ium bromide (VII) (617 g, 1.0 Eq, 1.91 mol) was dissolved in acetic acid (1.25 L) and a solution of bromine (306 g, 98.7 mL, 1.0 Eq, 1.91 mol) in acetic acid (625 mL) was added dropwise using a dropping funnel over 10 minutes.
- Step 3 2-amino-6-(1-(4-methoxybenzyl)-1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-ol
- IV 4-(2-amino-4-hydroxy-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-1-(4-methoxybenzyl)pyridin-1-ium bromide (V) (843.46 g, 1.0 Eq, 1.96 mol) was suspended in a mixed solvent of methanol (1.675 L) and pyridine (5.025 L), and sodium borohydride (223.5 g, 3.0 Eq, 5.9081 mol) was added little by little while stirring at room temperature.
- Step 5 N-(4-chloro-6-(1-(2,2,2-trifluoroacetyl)-1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)-2,2,2-trifluoroacetamide
- II 2,2,2-Trifluoro-N- ⁇ 4-hydroxy-6-[1-(2,2,2-trifluoroacetyl)-1,2,3,6-tetrahydropyridin-4-yl]-7H-pyrrolo[2,3-d]pyrimidin-2-yl ⁇ acetamide
- III (163.3 g, 1 Eq, 385.8 mmol), acetonitrile (500 mL), and phosphorus oxychloride (354.9 g, 215.7 mL, 6 Eq, 2.315 mol) were added to a three-necked round-bottom flask equipped with a mechanical stirrer and reflux condenser, and the
- Step 6 4-chloro-6-(1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine
- aqueous ammonia 154 g, 196 mL, 25.0% Wt, 20 Eq, 2.26 mol
- aqueous ammonia 154 g, 196 mL, 25.0% Wt, 20 Eq, 2.26 mol
- the white solid was isolated by suction filtration through a P3 filter, washed with acetonitrile, then diethyl ether, and transferred to a 250 mL round-bottom flask with acetonitrile. The mixture was concentrated under reduced pressure at 40-50° C. Yield: 26.89 g (95% yield).
- the mixture was stirred at 90°C for at least 1 hour, and then stirred at 20°C (internal temperature) for more than 2 hours.
- the product was collected by filtration, washed with DMSO-water (1.5:3), and washed with water. The product was dried under reduced pressure at 60°C to obtain the target product.
- the compound of the present invention is useful as a production intermediate of compound (A) having a BTK inhibitory activity. By using this intermediate, it becomes possible to produce compound (A) more economically and in higher yield.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/JP2022/047526 WO2024134859A1 (ja) | 2022-12-23 | 2022-12-23 | 製造中間体 |
| CN202280102676.4A CN120390749A (zh) | 2022-12-23 | 2022-12-23 | 制造中间体 |
| JP2024565529A JPWO2024134859A1 (https=) | 2022-12-23 | 2022-12-23 | |
| EP22969243.9A EP4640685A1 (en) | 2022-12-23 | 2022-12-23 | Production intermediate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/JP2022/047526 WO2024134859A1 (ja) | 2022-12-23 | 2022-12-23 | 製造中間体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2024134859A1 true WO2024134859A1 (ja) | 2024-06-27 |
Family
ID=91588205
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2022/047526 Ceased WO2024134859A1 (ja) | 2022-12-23 | 2022-12-23 | 製造中間体 |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP4640685A1 (https=) |
| JP (1) | JPWO2024134859A1 (https=) |
| CN (1) | CN120390749A (https=) |
| WO (1) | WO2024134859A1 (https=) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018097234A1 (ja) | 2016-11-25 | 2018-05-31 | カルナバイオサイエンス株式会社 | 新規オキソイソキノリン誘導体 |
-
2022
- 2022-12-23 JP JP2024565529A patent/JPWO2024134859A1/ja active Pending
- 2022-12-23 EP EP22969243.9A patent/EP4640685A1/en active Pending
- 2022-12-23 CN CN202280102676.4A patent/CN120390749A/zh active Pending
- 2022-12-23 WO PCT/JP2022/047526 patent/WO2024134859A1/ja not_active Ceased
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018097234A1 (ja) | 2016-11-25 | 2018-05-31 | カルナバイオサイエンス株式会社 | 新規オキソイソキノリン誘導体 |
Non-Patent Citations (3)
| Title |
|---|
| KAWAHATA WATARU, ASAMI TOKIKO, KIYOI TAKAO, IRIE TAKAYUKI, KASHIMOTO SHIGEKI, FURUICHI HATSUO, SAWA MASAAKI: "Discovery of AS-1763: A Potent, Selective, Noncovalent, and Orally Available Inhibitor of Bruton’s Tyrosine Kinase", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 64, no. 19, 14 October 2021 (2021-10-14), US , pages 14129 - 14141, XP055930428, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.1c01279 * |
| See also references of EP4640685A1 |
| STN Online REGISTRY; RN 261025-78-7; Year 2021 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN120390749A (zh) | 2025-07-29 |
| EP4640685A1 (en) | 2025-10-29 |
| JPWO2024134859A1 (https=) | 2024-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI453202B (zh) | 製備拉帕替尼之方法及中間體 | |
| CN105073716B (zh) | 嘧啶中间物的制备 | |
| JPWO2012043730A1 (ja) | モルホリノ核酸誘導体 | |
| CN1275575A (zh) | 合成核苷类似物的方法 | |
| JP7776478B2 (ja) | 核酸化合物の製造方法、及び、核酸化合物 | |
| CN111763209A (zh) | 一种芦可替尼的合成工艺 | |
| JP2023027091A (ja) | アミノピリミジン誘導体を調製するための改善されたプロセス | |
| CN111362939B (zh) | 一种帕布昔利布母核结构化合物的制备方法 | |
| CN107176955A (zh) | 一种巴瑞替尼的制备方法 | |
| WO2009133170A1 (en) | Process for the preparation of 5-(2-amino-pyrimidin-4-yl)-2-aryl-1h-pyrrole-3-carboxamides | |
| WO2024134859A1 (ja) | 製造中間体 | |
| CN101146810A (zh) | 制备1-取代的1H-咪唑并[4,5-c]喹啉-4-胺化合物的方法及其中间体 | |
| CN119707936A (zh) | 一种2,4-二取代-5-氟嘧啶衍生物的盐的制备方法 | |
| TW202527952A (zh) | 合成方法 | |
| HK40129684A (zh) | 制造中间体 | |
| CN110845406B (zh) | 喹啉类化合物的制备方法 | |
| CN117903032A (zh) | 一种巴瑞替尼中间体的制备方法及制备巴瑞替尼的方法 | |
| CN111205232B (zh) | 一种替格瑞洛中间体的合成方法 | |
| JP2007230963A (ja) | 2,4−ジ置換ピリジンの製造法 | |
| WO2017109524A1 (en) | Method and intermediate for the production of baricitinib | |
| CN105294573A (zh) | 一种合成4,6-二氯-2-(丙硫基)-5-氨基嘧啶的方法 | |
| JP2022517411A (ja) | テトラヒドロピリドピリミジン類の調製方法 | |
| KR20140071474A (ko) | 5-[2-[7-(트라이플루오로메틸)-5-[4-(트라이플루오로메틸)페닐]피라졸로[1,5-a]피리미딘-3-일]에틴일]-2-피리딘아민의 제조 방법 | |
| WO2013178020A1 (zh) | 一种制备依曲韦林的方法及其中间体 | |
| JP5079809B2 (ja) | (3−アルキル−5−ピペリジン−1−イル−3,3a−ジヒドロ−ピラゾロ[1,5−a]ピリミジン−7−イル)−アミノ誘導体および中間体の合成のための方法および合成のための中間体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22969243 Country of ref document: EP Kind code of ref document: A1 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2024565529 Country of ref document: JP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 202280102676.4 Country of ref document: CN |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 202547067330 Country of ref document: IN |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2022969243 Country of ref document: EP |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWP | Wipo information: published in national office |
Ref document number: 202547067330 Country of ref document: IN |
|
| ENP | Entry into the national phase |
Ref document number: 2022969243 Country of ref document: EP Effective date: 20250723 |
|
| WWP | Wipo information: published in national office |
Ref document number: 202280102676.4 Country of ref document: CN |
|
| ENP | Entry into the national phase |
Ref document number: 2022969243 Country of ref document: EP Effective date: 20250723 |
|
| ENP | Entry into the national phase |
Ref document number: 2022969243 Country of ref document: EP Effective date: 20250723 |
|
| WWP | Wipo information: published in national office |
Ref document number: 2022969243 Country of ref document: EP |